Antibody production
Introduction
Nowadays industrial production methods of antibodies involves the use of laboratory animals by exploding their immune systems ability to generate antibodies. Antibodies have a diverse set of applications and the ability to produce antibodies to fit a specific need is essential. Of the current techniques, the hybridoma technology is the most widely used method for producing monoclonal antibodies (mAb).
Antibodies – a part of the immune system
Antibodies are produced by B-lymphocytes of the adaptive immune system. They are highly specific proteins that remain surface-bound on the B-lymphocyte until it recognizes a foreign molecule like bacterial or viral proteins, generally termed an antigen. An antibody will recognize through binding a specific region of the antigen, called an
epitope ev
gene
The ability of antibodies to bind their target can be useful in treatment of cancer. Antibodies that bind and inhibit grow factors or blocking a hyperactive signalling pathway can potentially block tumor progression (6, 7). It has also been proposed to use antibodies as a drug delivery system by conjugating (linking) the antibody to a chemotherapeutic drug (6, 8). As of now, only few antibody-based treatments are available. Cancer cells have antigens on their surface which can be cancer specific or present at a higher concentration than on normal cells which potentially can be targeted by antibodies (6). The hope is that human-like antibodies against cancer antigens will be able to activate the immune system that in turn will eliminate the cancer cells like they were foreign material.
It is no surprise why scientists, researchers and doctors are interested in this sophisticated and elegant molecule and why they would want to have antibodies produce at command to fit their needs.
However, the available methods for producing antibodies are less sophisticated and elegant ethically speaking and stain the reputation of antibodies. The most widely used method for producing monoclonal antibodies is the hybridoma technology.
Industrial production of monoclonal antibodies using the hybridoma technology
Monoclonal antibodies are produced from one B-lymphocyte cell line (clones), and the antibodies produced will have affinity for the same epitope on the antigen. This means that they will recognize and bind the same region of the antigen. mAb are preferable to polyclonal antibodies in the field of research.
The hybridoma technology was originally developed by Kohler and Milstein in 1975 (9) and relies on an animals ability to generate antibodies against a foreign molecule. The animal of choice in production of monoclonal antibodies is typically a mouse or a rabbit. This production method involves 6 general steps (10);
- Immunization: Injection of the antigen into the animal continuously for several weeks. Often the animals are also injected with an adjuvant that enhances the immune response (11).
- Isolation: Euthanizing and extracting the blood (in polyclonal antibody production) and spleen from the animal and isolation of the antibody producing B-lymphocytes.
- Fusion: Fusion of the B-lymphocytes from the spleen and a murine myeloma cell line (B-lymphocyte cancer cells), thus creating immortal and high-yield antibody producing hybrid cells.
- Screening: Affinity based screening tests of the different antibodies to select the most effective one. This involves techniques such as ELISA and are followed by affinity chromatography purification(5).
- Multiplication: Growing of selected hybridoma cell in a culture dish or transplantation of the tumor cells into a new animal for a higher yield. The latter is the typical procedure.
- Harvesting: The hybridoma cells will mass produce their antibody and mass divide. This causes tumor development and accumulation of fluids in the abdominal cavities (ascites). The fluid can be drained and the antibodies harvested from it.
Antibodies generated in the murine model will have to be further modified before they can be used therapeutically in humans. The murine antibodies will be recognized as foreign in humans and will elicit an immune response against murine antibody. Before mouse antibodies (or any other animal antibody) can be used in clinical medicine, they have to be ‘humanized’. Humanized animal antibodies are also known as chimeric antibodies (6) and are generated by combining the constant part of a human antibody with the variable (epitope-recognizing) part of the murine antibody. However chimeric antibodies are still about 30 % foreign for the human body, and therefore they elicit significant immunogenicity in humans (6). Creation of chimeric and humanized antibodies is not as easy as it might sound. It requires extensive knowledge and characterisation of the antibody structure and effective methods are still limited (6).
